In vitro and in vivo assessment of heart-homing porous silicon nanoparticles.

Chronic heart failure, predominantly developed after myocardial infarction, is a leading cause of high mortality worldwide. As existing therapies have still limited success, natural and/or synthetic nanomaterials are emerging alternatives for the therapy of heart diseases. Therefore, we aimed to functionalize undecylenic acid thermally hydrocarbonized porous silicon nanoparticles (NPs) with different targeting peptides to improve the NP's accumulation in different cardiac cells (primary cardiomyocytes, non-myocytes, and H9c2 cardiomyoblasts), additionally to investigate the behavior of the heart-targeted NPs in vivo. The toxicity profiles of the NPs evaluated in the three heart-type cells showed low toxicity at concentrations up to 50 μg/mL. Qualitative and quantitative cellular uptake revealed a significant increase in the accumulation of atrial natriuretic peptide (ANP)-modified NPs in primary cardiomyocytes, non-myocytes and H9c2 cells, and in hypoxic primary cardiomyocytes and non-myocytes. Competitive uptake studies in primary cardiomyocytes showed the internalization of ANP-modified NPs takes place via the guanylate cyclase-A receptor. When a myocardial infarction rat model was induced by isoprenaline and the peptide-modified [(111)In]NPs administered intravenously, the targeting peptides, particularly peptide 2, improved the NPs' accumulation in the heart up to 3.0-fold, at 10 min. This study highlights the potential of these peptide-modified nanosystems for future applications in heart diseases.

[1]  Thomas Lavergne,et al.  Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. , 2002, Journal of the American College of Cardiology.

[2]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[3]  Xiongbin Lin,et al.  Gene expression of natriuretic peptide receptors in myocardial cells. , 1995, Circulation research.

[4]  H M Patel,et al.  Serum opsonins and liposomes: their interaction and opsonophagocytosis. , 1992, Critical reviews in therapeutic drug carrier systems.

[5]  Bruno Sarmento,et al.  The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium. , 2014, Biomaterials.

[6]  A. Vengellur,et al.  The role of hypoxia inducible factor 1alpha in cobalt chloride induced cell death in mouse embryonic fibroblasts. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[7]  Joseph C. Wu,et al.  Biomaterial applications in cardiovascular tissue repair and regeneration , 2012, Expert review of cardiovascular therapy.

[8]  Bozhi Tian,et al.  Silicon nanowire-induced maturation of cardiomyocytes derived from human induced pluripotent stem cells. , 2015, Nano letters.

[9]  Alexander M. Seifalian,et al.  Toxicology and clinical potential of nanoparticles , 2011, Nano today.

[10]  P. Yotnda,et al.  Induction and testing of hypoxia in cell culture. , 2011, Journal of visualized experiments : JoVE.

[11]  M. Beckerle,et al.  Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. , 2005, The Journal of clinical investigation.

[12]  M C Oz,et al.  Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.

[13]  B. Gaihre,et al.  In-vitro cytotoxicity and cell uptake study of gelatin-coated magnetic iron oxide nanoparticles , 2011, Journal of microencapsulation.

[14]  Miroslav Machala,et al.  Global gene expression changes in human embryonic lung fibroblasts induced by organic extracts from respirable air particles , 2012, Particle and Fibre Toxicology.

[15]  P. Netti,et al.  Effect of silica nanoparticles with variable size and surface functionalization on human endothelial cell viability and angiogenic activity , 2014, Journal of Nanoparticle Research.

[16]  Iseult Lynch,et al.  Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.

[17]  A. Vengellur,et al.  The Role of Hypoxia Inducible Factor 1α in Cobalt Chloride Induced Cell Death in Mouse Embryonic Fibroblasts , 2004 .

[18]  Bruno Sarmento,et al.  A prospective cancer chemo-immunotherapy approach mediated by synergistic CD326 targeted porous silicon nanovectors , 2015, Nano Research.

[19]  E. Olson,et al.  Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair , 2013, Nature Reviews Molecular Cell Biology.

[20]  M. Maynadier,et al.  Anionic porphyrin-grafted porous silicon nanoparticles for photodynamic therapy. , 2013, Chemical communications.

[21]  S. Mather,et al.  Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes , 2006, Nature Protocols.

[22]  Francesco Stellacci,et al.  Effect of surface properties on nanoparticle-cell interactions. , 2010, Small.

[23]  O. Eniola-Adefeso,et al.  Design of nanovectors for therapy and imaging of cardiovascular diseases. , 2012, Methodist DeBakey cardiovascular journal.

[24]  Mauro Ferrari,et al.  Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. , 2008, Nature nanotechnology.

[25]  M. Jessup,et al.  Heart failure. , 2003, The New England journal of medicine.

[26]  Jarno Salonen,et al.  Nanostructured Porous Silicon‐Solid Lipid Nanocomposite: Towards Enhanced Cytocompatibility and Stability, Reduced Cellular Association, and Prolonged Drug Release , 2013 .

[27]  Michael J Sailor,et al.  Biodegradable luminescent porous silicon nanoparticles for in vivo applications. , 2009, Nature materials.

[28]  G. Trachte.  Atrial natriuretic factor alters neurotransmission independently of guanylate cyclase-coupled receptors in the rabbit vas deferens. , 1993, The Journal of pharmacology and experimental therapeutics.

[29]  F. Prósper,et al.  Heart regeneration after myocardial infarction using synthetic biomaterials. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[30]  H. Santos,et al.  In vitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size. , 2010, Acta biomaterialia.

[31]  Hélder A Santos,et al.  Multifunctional porous silicon nanoparticles for cancer theranostics. , 2015, Biomaterials.

[32]  Richard T. Lee,et al.  Identification of targeting peptides for ischemic myocardium by in vivo phage display. , 2011, Journal of molecular and cellular cardiology.

[33]  Y. Korchev,et al.  Functional interaction between charged nanoparticles and cardiac tissue: a new paradigm for cardiac arrhythmia? , 2013, Nanomedicine.

[34]  Mónica P. A. Ferreira,et al.  In vivo biocompatibility of porous silicon biomaterials for drug delivery to the heart. , 2014, Biomaterials.

[35]  Lin Wei,et al.  Annealing effect on photovoltaic performance of CdSe quantum-dots-sensitized TiO 2 nanorod solar cells , 2012 .

[36]  Mauro Ferrari,et al.  Sustained small interfering RNA delivery by mesoporous silicon particles. , 2010, Cancer research.

[37]  P. P. Lottici,et al.  Particle and Fibre Toxicology Particle and Fibre Toxicology Titanium Dioxide Nanoparticles Promote Arrhythmias via a Direct Interaction with Rat Cardiac Tissue Titanium Dioxide Nanoparticles Promote Arrhythmias via a Direct Interaction with Rat Cardiac Tissue , 2022 .

[38]  H. Dargie.  Heart failure post-myocardial infarction: a review of the issues , 2005, Heart.

[39]  Hélder A Santos,et al.  Tumour homing peptide-functionalized porous silicon nanovectors for cancer therapy. , 2013, Biomaterials.

[40]  Fabrication and characterization of a chemically oxidized-nanostructured porous silicon based biosensor implementing orienting protein A. , 2014, Colloids and surfaces. B, Biointerfaces.

[41]  Jun Wu,et al.  Surgical ventricular restoration with a cell- and cytokine-seeded biodegradable scaffold. , 2010, Biomaterials.

[42]  H. Ruskoaho.  Atrial natriuretic peptide: synthesis, release, and metabolism. , 1992, Pharmacological reviews.

[43]  W. Weber,et al.  Anantin--a peptide antagonist of the atrial natriuretic factor (ANF). I. Producing organism, fermentation, isolation and biological activity. , 1991, The Journal of antibiotics.

[44]  A. Närvänen,et al.  Functionalization of mesoporous silicon nanoparticles for targeting and bioimaging purposes , 2012 .

[45]  L. R. Potter,et al.  Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. , 2009, Handbook of experimental pharmacology.

[46]  P. Comoglio,et al.  Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy , 2014, Cell Death and Disease.

[47]  Mark D. Huffman,et al.  AHA Statistical Update Heart Disease and Stroke Statistics — 2012 Update A Report From the American Heart Association WRITING GROUP MEMBERS , 2010 .

[48]  C. Yang,et al.  Peptide modified gold nanoparticles for improved cellular uptake, nuclear transport, and intracellular retention. , 2014, Nanoscale.

[49]  Yanli Liu,et al.  Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. , 2004, Bioconjugate chemistry.

[50]  Cytotoxicity and cellular uptake of tri-block copolymer nanoparticles with different size and surface characteristics , 2012, Particle and Fibre Toxicology.

[51]  J. Salonen,et al.  Stabilization of porous silicon surface by thermal decomposition of acetylene , 2004 .

[52]  N. Monteiro-Riviere,et al.  Variables influencing interactions of untargeted quantum dot nanoparticles with skin cells and identification of biochemical modulators. , 2007, Nano letters.

[53]  D. Delurgio,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[54]  Sara Linse,et al.  Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[55]  J. Nerbonne,et al.  Molecular physiology of cardiac repolarization. , 2005, Physiological reviews.

[56]  V. Lehto,et al.  Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[57]  M. Ferrari,et al.  Porous silicon microparticles for delivery of siRNA therapeutics. , 2015, Journal of visualized experiments : JoVE.

[58]  Mónica P. A. Ferreira,et al.  Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure. , 2015, Current drug targets.

[59]  Jarno Salonen,et al.  On‐Chip Self‐Assembly of a Smart Hybrid Nanocomposite for Antitumoral Applications , 2015 .

[60]  Vesa-Pekka Lehto,et al.  Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. , 2010, ACS nano.

[61]  M. Ferrari,et al.  In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice. , 2010, International journal of pharmaceutics.

[62]  Michael S. Strano,et al.  Size-dependent cellular uptake and expulsion of single-walled carbon nanotubes: single particle tracking and a generic uptake model for nanoparticles. , 2009, ACS nano.

[63]  M. Brown,et al.  Natriuretic peptide receptor mRNAs in the rat and human heart. , 1992, The Journal of clinical investigation.

[64]  F. Crampes,et al.  Functional and Pharmacological Characterization of the Natriuretic Peptide-Dependent Lipolytic Pathway in Human Fat Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[65]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[66]  A. L. Nikolaev,et al.  Porous Silicon Nanoparticles as Efficient Sensitizers for Sonodynamic Therapy of Cancer , 2015 .

[67]  Patrick V. Almeida,et al.  The mechanisms of surface chemistry effects of mesoporous silicon nanoparticles on immunotoxicity and biocompatibility. , 2013, Biomaterials.

[68]  Katharina Landfester,et al.  Synthesis and biomedical applications of functionalized fluorescent and magnetic dual reporter nanoparticles as obtained in the miniemulsion process , 2006 .

[69]  Seungpyo Hong,et al.  Nanoparticle interaction with biological membranes: does nanotechnology present a Janus face? , 2007, Accounts of chemical research.

[70]  M. Varfolomeev,et al.  Enthalpy of cooperative hydrogen bonding in complexes of tertiary amines with aliphatic alcohols: Calorimetric study , 2011 .

[71]  M. Raghunath,et al.  Microcapsules engineered to support mesenchymal stem cell (MSC) survival and proliferation enable long-term retention of MSCs in infarcted myocardium. , 2015, Biomaterials.

[72]  E. Vellaichamy,et al.  Angiotensin II down-regulates natriuretic peptide receptor-A expression and guanylyl cyclase activity in H9c2 (2-1) cardiac myoblast cells: Role of ROS and NF-κB , 2015, Molecular and Cellular Biochemistry.

[73]  H. Santos,et al.  Nanostructured porous silicon materials: potential candidates for improving drug delivery. , 2012, Nanomedicine.

[74]  A. Curcio,et al.  Acute β-Adrenergic Overload Produces Myocyte Damage through Calcium Leakage from the Ryanodine Receptor 2 but Spares Cardiac Stem Cells* , 2007, Journal of Biological Chemistry.

[75]  D. Gardner,et al.  Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. , 1995, Hypertension.

[76]  Patrick V. Almeida,et al.  Augmented cellular trafficking and endosomal escape of porous silicon nanoparticles via zwitterionic bilayer polymer surface engineering. , 2014, Biomaterials.

[77]  Javier I. Amalvy,et al.  ポリウレタン/PTFEナノ粒子のコンポジットとナノコンポジットの表面特性,熱特性,および機械的特性 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター , 2014 .